Paratek Pharmaceuticals to Present at the Cowen and Company 39th Annual Health Care Conference
March 01, 2019 08:00 ET
|
Paratek Pharmaceuticals
BOSTON, March 01, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative...
Paratek Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results
February 27, 2019 16:01 ET
|
Paratek Pharmaceuticals
-- NUZYRA™ (omadacycline) Launched in the United States for the Treatment of CABP and ABSSSI -- -- New England Journal of Medicine Publishes Results from Two Pivotal Phase 3 Studies of NUZYRA -- --...
Paratek Pharmaceuticals to Present at the 8th Annual SVB Leerink Global Healthcare Conference
February 14, 2019 16:05 ET
|
Paratek Pharmaceuticals
BOSTON, Feb. 14, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative...
Paratek Pharmaceuticals to Report Fourth Quarter and Full Year 2018 Financial Results on February 27, 2019
February 13, 2019 16:05 ET
|
Paratek Pharmaceuticals
BOSTON, Feb. 13, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative...
New England Journal of Medicine Publishes Results from Pivotal Phase 3 Studies of Paratek’s NUZYRA™ (Omadacycline) For Pneumonia and Skin Infections
February 06, 2019 17:05 ET
|
Paratek Pharmaceuticals
BOSTON, Feb. 06, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based...
Paratek Pharmaceuticals Launches NUZYRA™ (Omadacycline) in the United States
February 05, 2019 16:05 ET
|
Paratek Pharmaceuticals
-- Three Antimicrobial Susceptibility Tests Cleared by FDA for Use with NUZYRA -- -- Launches KEYSTONETM Surveillance Program to Monitor Omadacycline Susceptibility -- BOSTON, Feb. 05, 2019 ...
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
February 01, 2019 16:01 ET
|
Paratek Pharmaceuticals
BOSTON, Feb. 01, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today...
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
January 02, 2019 16:01 ET
|
Paratek Pharmaceuticals
BOSTON, Jan. 02, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today...
Paratek Pharmaceuticals Files Two Patent Term Extensions in the United States; Expects NUZYRA™ Patent Protection Exclusivity Until at Least October 2030
December 03, 2018 16:01 ET
|
Paratek Pharmaceuticals
BOSTON, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative...
Paratek Pharmaceuticals Doses First Patient in Phase 2 Clinical Trial of Omadacycline in Acute Pyelonephritis, a Common Subset of Complicated Urinary Tract Infections
November 27, 2018 08:00 ET
|
Paratek Pharmaceuticals
BOSTON, Nov. 27, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative...